RNXT · RenovoRx, Inc.
$0.94
+0.04 (+4.76%)
At close · Jul 30
Market Cap
$40.46M
Shares
45.05M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.90
Open$0.91
Day$0.89–0.93
52W$0.70–1.45
Avg vol 30d216K
Short int328K · 0.7% float · 1.7d
Short vol43%
Last earningsAug 12, 2026
DataAug 2021–Jul 2026
Filing10-Q · May 14
Up next
Next earnings call
Aug 12, 2026
Scheduled
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−0%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
26%
mid-range
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−7%
trailing
YTD return
+7%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
8 of 31 funds reported for Jun 30 · net -87.4K sh shares · +2 new
Insider flow
Accumulating
Net +$19.7K over 90 days · 0% sells
Short interest
Falling
0.73% of float · ▼ -5.2% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
31 holders — mid 3-yr range
Squeeze score
37
low risk · 0–100
Fundamentals
Revenue growth
+2512%
Y/Y
Gross margin
71%
contracting
EPS growth
+20%
Y/Y
Free cash flow
$-11.0M
Balance sheet
$7.0M
net cash
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
2026 revenue
· full year 2026
Initiated
$3M – $4M
prior FY $1.12M
midpoint +211.7% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
−0%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
26%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
8 of 31 funds reported for Jun 30 · net -87.4K sh shares · +2 new
Insider flow
Accumulating
Net +$19.7K over 90 days · 0% sells
Short interest
Falling
0.73% of float · ▼ -5.2% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
31 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 26%
52-wk high $1
vs 200-day avg -5%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active commercial cancer centers | 16 | Q1 2026 | — |
| Patients randomized in TIGeR-PaC trial | 106 | Q1 2026 | — |
| Total cancer centers (active + evaluating/preparing for activation) | 48 | Q1 2026 | — |
| Active U.S. cancer centers utilizing RenovoCath | 12 | as of February 27, 2026 | — |
| Additional cancer centers evaluating, having completed evaluation, or preparing for activation | 21 | as of February 27, 2026 | — |
| Cash on hand | $13M | as of March 30, 2026 | — |
| Events (deaths) observed in TIGeR-PaC trial | 72 | as of March 24, 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNXT
this stock
RenovoRx, Inc.
|
$40.46M | +6.9% | +2511.6% | — | 0.7% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.5 | 3.4% |
|
ARGX
Argenx SE
|
$54.59B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNXT | +3.7% | -8.4% | -6.9% | -8.4% | +6.9% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +6.1% | -6.1% | -13.3% | -6.1% | -0.1% |